2019
The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study
Park SI, Horwitz SM, Foss FM, Pinter‐Brown L, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR, Investigators F. The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer 2019, 125: 1507-1517. PMID: 30694529, PMCID: PMC8269282, DOI: 10.1002/cncr.31861.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesFemaleHematopoietic Stem Cell TransplantationHumansImmunoblastic LymphadenopathyLymphatic MetastasisLymphoma, T-Cell, PeripheralMaleMiddle AgedRemission InductionRetrospective StudiesTransplantation, AutologousYoung AdultConceptsAutologous stem cell transplantationPeripheral T-cell lymphomaNodal peripheral T-cell lymphomaAngioimmunoblastic T-cell lymphomaT-cell lymphomaConsolidative autologous stem cell transplantationFirst complete remissionStem cell transplantationComplete remissionCohort studyCell transplantationImpact of ASCTAggressive peripheral T-cell lymphomaFirst large prospective cohort studyHigh International Prognostic Index scoreUntreated peripheral T-cell lymphomaAnaplastic lymphoma kinase-negative anaplastic large cell lymphomaInternational Prognostic Index scoreLarge prospective cohort studyAnaplastic large cell lymphomaComprehensive Oncology MeasuresMedian overall survivalMulticenter cohort studyAdvanced stage diseaseProgression-free survival
2018
Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study
O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I. Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. American Journal Of Hematology 2018, 93: 1318-1326. PMID: 30094870, PMCID: PMC8260004, DOI: 10.1002/ajh.25243.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaPhase 1 studyTN patientsRR patientsLymphocytic lymphomaLymphocytic leukemiaRefractory chronic lymphocytic leukemiaMedian response durationAdvanced hematologic malignanciesPhase 3 studyOverall response rateCLL/SLLSmall lymphocytic lymphomaPatient's diarrheaExpansion cohortTransaminase elevationHematologic malignanciesPharmacodynamic activityResponse durationPatientsResponse rateΓ inhibitorDuvelisibDual inhibitorLymphoma
2017
Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T‐cell lymphoma: long‐term remission after brentuximab vedotin
Cyrenne BM, Subtil A, Girardi M, Foss F. Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T‐cell lymphoma: long‐term remission after brentuximab vedotin. International Journal Of Dermatology 2017, 56: 1448-1450. PMID: 29047111, DOI: 10.1111/ijd.13792.Peer-Reviewed Original Research
2016
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. Journal Of Hematology & Oncology 2016, 9: 22. PMID: 26965915, PMCID: PMC4785666, DOI: 10.1186/s13045-016-0243-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibiotics, AntineoplasticDepsipeptidesDisease ProgressionDisease-Free SurvivalDrug Administration ScheduleDrug Resistance, NeoplasmFatigueFemaleHistone Deacetylase InhibitorsHumansLymphoma, T-Cell, PeripheralMaleMiddle AgedNauseaNeoplasm Recurrence, LocalNeutropeniaRemission InductionTime FactorsTreatment OutcomeYoung AdultConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaStable diseaseT-cell lymphomaClinical benefitPivotal trialsCell lymphomaDay 1Good responseLong stable diseaseObjective response rateProgression-free survivalUnconfirmed complete responseT-cell malignanciesHistone deacetylase inhibitorsProlonged dosingDurable responsesMedian durationObjective responsePartial responseComplete responseCurrent therapiesProtocol amendmentCell malignanciesPatients
2015
Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma
Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica 2015, 100: 794-800. PMID: 25795722, PMCID: PMC4450625, DOI: 10.3324/haematol.2015.123711.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaComplete remissionRecombinant immunotoxinCommon adverse eventsDose-escalation trialLow tumor burdenAssessment Tool scoreDurable remissionsEscalation trialPartial remissionAdverse eventsTumor burdenIntravenous infusionPatientsRemissionTool scoreResponse rateSingle-chain antibody fragmentChain antibody fragmentsLymphomaDiphtheria toxinFurther studiesImmunotoxinTrialsUtility of18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma
Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B. Utility of18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Annals Of Oncology 2015, 26: 774-779. PMID: 25605745, PMCID: PMC4374388, DOI: 10.1093/annonc/mdv010.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaInternational Workshop CriteriaFDG-PET scansRefractory peripheral T-cell lymphomaBaseline FDG-PET scanCR/CRuT-cell lymphomaPositron emission tomographyConventional radiologyPET criteriaStable diseaseEnd pointFDG-PETConventional stagingPET statusResponse assessmentPivotal phase 2 trialEmission tomographyDeoxyglucose positron emission tomographyExploratory end pointsObjective response ratePET-positive diseasePrimary end pointProgression-free survivalPhase 2 study
2014
CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature
James E, Sokhn JG, Gibson JF, Carlson K, Subtil A, Girardi M, Wilson LD, Foss F. CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature. Leukemia & Lymphoma 2014, 56: 951-957. PMID: 24996443, DOI: 10.3109/10428194.2014.938331.Peer-Reviewed Original ResearchConceptsT-cell lymphomaSmall/medium-sized pleomorphic T-cell lymphomaPleomorphic T-cell lymphomaPCSM-TCLSystemic involvementCase seriesWorld Health Organization-European OrganizationIndolent T-cell lymphomaRare T-cell lymphomaLocalized radiationRetrospective case seriesCD7 lossReview of literatureComplete remissionCytotoxic chemotherapyMedian ageFavorable prognosisRetrospective studyTreatment of cancerExcisional biopsyCD4Local modalitiesPatientsLymphomaInvasive featuresRomidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. Journal Of Hematology & Oncology 2014, 7: 11. PMID: 24456586, PMCID: PMC4016573, DOI: 10.1186/1756-8722-7-11.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibiotics, AntineoplasticCellulitisDepsipeptidesDisease-Free SurvivalDrug Administration ScheduleDrug Resistance, NeoplasmFemaleHumansInfusions, IntravenousLymphoma, T-Cell, PeripheralMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesRemission InductionTime FactorsTreatment OutcomeVenous ThrombosisVomitingConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaCR/CRuDuration of responseObjective response rateT-cell lymphomaDurable responsesPrior therapySystemic therapyMedian DORMedian progression-free survivalCutaneous T-cell lymphomaReported safety profileProgression-free survivalUnconfirmed complete responseSubset of patientsLong-term responseIndependent review committeeTreatment of patientsSelective histone deacetylase inhibitorsHistone deacetylase inhibitorsLack of responseHeavy pretreatmentStable diseasePrimary endpoint
2003
Denileukin Diftitox and Hyper-CVAD in the Treatment Human T-Cell Lymphotropic Virus 1–Associated Adult T-Cell Leukemia/Lymphoma
DiVenuti G, Nawgiri R, Foss F. Denileukin Diftitox and Hyper-CVAD in the Treatment Human T-Cell Lymphotropic Virus 1–Associated Adult T-Cell Leukemia/Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2003, 4: 176-178. PMID: 14715100, DOI: 10.3816/clm.2003.n.027.Peer-Reviewed Original ResearchConceptsAdult T-cell leukemia/lymphomaT-cell leukemia/lymphomaDenileukin diftitoxLeukemia/lymphomaClinical remissionHuman T-cell lymphotropic virus-1Human T-cell lymphotropic virusCell leukemia/lymphomaBone marrow myelofibrosisComplete clinical remissionBone marrow biopsyLymphotropic virus-1Acute T-cell leukemiaNormal hematopoiesisT-cell leukemiaLeukemic T cellsExtensive myelofibrosisHyper-CVADInitial therapyMaintenance therapyClinical improvementClinical manifestationsMarrow biopsyDisease progressionT cellsReduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease
Chan GW, Foss FM, Klein AK, Sprague K, Miller KB. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Transplantation And Cellular Therapy 2003, 9: 753-759. PMID: 14677114, DOI: 10.1016/j.bbmt.2003.08.002.Peer-Reviewed Original ResearchConceptsAcute GVHDHost diseasePreparative regimenExcess blastsAllogeneic transplantationDisease relapseGrade IIAllogeneic stem cell infusionReduced-intensity allogeneic transplantationReduced-intensity preparative regimenAllogeneic bone marrow transplantationHigh-risk MDS patientsExtensive chronic GVHDReduced-intensity transplantationTransplant-related mortalityFull donor chimerismTreatment-related mortalityStem cell infusionBone marrow transplantationMyelodysplastic syndrome patientsChronic myelomonocytic leukemiaSuccessful donor engraftmentChronic GVHDGVHD prophylaxisLess graft